1. Home
  2. CDTX

CDTX

Cidara Therapeutics Inc.

Logo Cidara Therapeutics Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 3:58pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.

Founded: 2012 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 83.4M IPO Year: 2015
Target Price: $4.67 AVG Volume (30 days): 695.8K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.39 EPS Growth: N/A
52 Week Low/High: $0.59 - $1.48 Next Earning Date: 05-09-2024
Revenue: $56,541,000 Revenue Growth: -7.75%
Revenue Growth (this year): -8.22% Revenue Growth (next year): -63.57%

Share on Social Networks: